STOCK TITAN

ONCS - ONCS STOCK NEWS

Welcome to our dedicated page for ONCS news (Ticker: ONCS), a resource for investors and traders seeking the latest updates and insights on ONCS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONCS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONCS's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.83%
Tags
none
Rhea-AI Summary

OncoSec Medical announced the receipt of $3.49 million in tax credit certificates from the New Jersey Economic Development Authority on April 27, 2023. This funding comes through the NJEDA's Technology Business Tax Certificate Transfer Program, which assists biotechnology firms in New Jersey by allowing them to sell unused net operating losses (NOLs) and research tax credits for cash. OncoSec's CEO, Robert H. Arch, praised the program for providing non-dilutive funding that supports the advancement of OncoSec's interleukin 12 (IL-12) encoding plasmid therapy, crucial for cancer treatment development, particularly in melanoma. The company continues to focus on its lead immunotherapy product, TAVO™, aiming to stimulate immune responses against cancer cells.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

OncoSec Medical (NASDAQ: ONCS) announced a registered direct offering of 1,582,932 shares at $1.25 each, aiming to raise approximately $2 million before fees. This offering includes concurrent private placement warrants to purchase up to the same number of shares at an exercise price of $1.12. The closing is anticipated around April 12, 2023, subject to customary conditions. The gross proceeds will support general corporate purposes. This offering utilizes a registration statement effective as of November 15, 2021, under the Securities Act. Investors should note that these securities are not registered for sale in the United States unless exempt under applicable laws.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.39%
Tags
-
Rhea-AI Summary

OncoSec Medical (NASDAQ: ONCS) announced primary endpoint data from the Phase 2 KEYNOTE-695 trial evaluating TAVO™-EP combined with KEYTRUDA in patients with unresectable melanoma. The overall response rate (ORR) of 10.2% fell short of the pre-specified rate of ≥17%. Although 35.7% of patients demonstrated disease control, the median overall survival was reported at 22.7 months. The treatment was generally well tolerated, with Grade 3 adverse events at 4.8%. OncoSec plans to pursue TAVO™-EP in the neoadjuvant setting, supported by promising interim data from an investigator-sponsored trial, with an FDA meeting scheduled for May 2023 to discuss further development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.61%
Tags
Rhea-AI Summary

OncoSec Medical, a clinical-stage biotechnology company, announced that its CEO, Robert Arch, will participate in the RHK Capital Disruptive Growth Conference in New York City on December 6, 2022, at 1:40 pm ET. The conference will showcase approximately 30 growth-oriented companies to institutional and accredited investors. OncoSec is focused on developing intratumoral immunotherapies, particularly its lead candidate, TAVO™, which uses electroporation for localized immune response in cancer treatment. For webcast access, visit this link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
conferences
-
Rhea-AI Summary

OncoSec Medical announced a public offering of 1,166,667 shares of common stock and warrants to purchase an equal number of shares at $3.00 each, aiming for gross proceeds of $3.5 million. The offering is expected to close by December 1, 2022, pending customary conditions. Funds will support working capital, operations, R&D, and possible acquisitions. The offering is registered under SEC Form S-1, effective November 30, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.49%
Tags
-
Rhea-AI Summary

OncoSec Medical (NASDAQ: ONCS) announced early clinical data from an investigator-sponsored trial of TAVO™-EP, an IL-12 encoding plasmid delivered intratumorally, in combination with nivolumab for treating operable melanoma. Interim results, presented at the SITC Annual Meeting, showed a 70% overall response rate, with 66.7% achieving a pathological complete response. No severe treatment-related adverse events were reported, indicating a favorable safety profile. The trial aims to evaluate TAVO™-EP's potential in neoadjuvant settings, addressing unmet needs in melanoma treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
none
Rhea-AI Summary

OncoSec Medical (NASDAQ: ONCS) announced positive results from the Phase 2 KEYNOTE-695 trial assessing TAVO™-EP combined with pembrolizumab for advanced melanoma patients who failed prior anti-PD-1 therapy. The trial met its key secondary endpoint, showing an overall response rate (ORR) of 18.8%, surpassing the pre-specified target of 17%. With a disease control rate of 40.6%, results indicate a median overall survival of 22.7 months. The therapy was generally well tolerated, with no severe adverse events reported, highlighting its potential as a viable treatment option for this challenging patient group.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.16%
Tags

FAQ

What is the market cap of ONCS (ONCS)?

The market cap of ONCS (ONCS) is approximately 1.7M.

ONCS

Nasdaq:ONCS

ONCS Rankings

ONCS Stock Data

1.65M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Pennington